Fibric acids: effects on lipids and lipoprotein metabolism
- PMID: 3318457
- DOI: 10.1016/0002-9343(87)90866-7
Fibric acids: effects on lipids and lipoprotein metabolism
Abstract
The major effect of the fibrates on triglycerides is to promote triglyceride-rich lipoprotein catabolism through increased lipoprotein lipase activity. Fibrates also enhance lipolysis of plasma triglycerides by a means different from that of caloric restriction. Their effect on very low-density lipoprotein metabolism also differs from that of nicotinic acid. The effect of fibrate therapy upon low-density lipoprotein-cholesterol concentrations depends upon the patients' overall lipoprotein status. The responsible mechanisms are not understood. In hypertriglyceridemic patients, fibrates often reverse abnormal changes in low-density lipoprotein composition; low-density lipoprotein heterogeneity is reduced and small dense low-density lipoproteins are eliminated, apparently secondary to reduced levels of triglyceride-rich lipoproteins. Kinetic studies indicate that fibrates do not enhance low-density lipoprotein formation rates, thus contradicting the idea that fibrate therapy causes increased low-density lipoprotein cholesterol levels via increased conversion of very low-density lipoprotein to low-density lipoprotein. Though enhanced low-density lipoprotein catabolism in hypertriglyceridemia could occur via several mechanisms, the responsible factors are largely reversed by fibrate therapy. In non-hypertriglyceridemic patients, fibrates may actually enhance the fractional clearance of low-density lipoprotein and thus reduce low-density lipoprotein levels. Fibrate therapy reverses the typical high-density lipoprotein pattern of hypertriglyceridemic patients, producing more high-density lipoprotein2a and less high-density lipoprotein2b. Such treatment also increases high-density lipoprotein cholesterol levels in patients without definite hypertriglyceridemia. Synthesis rates of apolipoproteins AI and AII may be affected by fibrates. The fibrates' major effects on sterol metabolism are interference with cholesterol and bile acid synthesis and increased cholesterol secretion into bile. Although bile saturation increases in most patients, in only a relatively small percentage do gallstones actually develop; super-saturated bile is not sufficient to induce gallstone formation in most patients. Available data strongly imply that fibrates mobilized cholesterol out of tissue pools, perhaps by altering tissue cell membranes to allow cholesterol release from the cell surfaces.
Similar articles
-
Fibrates and triglyceride metabolism.Eur J Clin Pharmacol. 1991;40 Suppl 1:S41-3. Eur J Clin Pharmacol. 1991. PMID: 2044642
-
Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.Biochem Pharmacol. 1992 Feb 4;43(3):625-33. doi: 10.1016/0006-2952(92)90586-8. Biochem Pharmacol. 1992. PMID: 1311585
-
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.Eur J Clin Pharmacol. 1991;40(1):33-41. doi: 10.1007/BF00315136. Eur J Clin Pharmacol. 1991. PMID: 2060543
-
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.J Clin Pharmacol. 1991 Jan;31(1):25-37. doi: 10.1002/j.1552-4604.1991.tb01883.x. J Clin Pharmacol. 1991. PMID: 2045526 Review.
-
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.Am J Med. 1987 Nov 27;83(5B):66-70. doi: 10.1016/0002-9343(87)90873-4. Am J Med. 1987. PMID: 3318456 Review.
Cited by
-
Optimal lipid modification: the rationale for combination therapy.Vasc Health Risk Manag. 2005;1(4):317-31. doi: 10.2147/vhrm.2005.1.4.317. Vasc Health Risk Manag. 2005. PMID: 17315604 Free PMC article. Review.
-
Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.Klin Wochenschr. 1991 Sep 3;69(13):618-22. doi: 10.1007/BF01649325. Klin Wochenschr. 1991. PMID: 1753684 Review.
-
Reduction of BM 15.766-induced 7-dehydrocholesterol accumulation by bezafibrate and mevinolin in rats. A non-isotopic in vivo test system for compounds reducing cholesterol synthesis.Naunyn Schmiedebergs Arch Pharmacol. 1990 Jun;341(6):552-6. doi: 10.1007/BF00171736. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 2392158
-
Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7242-6. doi: 10.1073/pnas.93.14.7242. Proc Natl Acad Sci U S A. 1996. PMID: 8692976 Free PMC article.
-
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.Atherosclerosis. 2016 Apr;247:35-39. doi: 10.1016/j.atherosclerosis.2016.01.028. Epub 2016 Jan 22. Atherosclerosis. 2016. PMID: 26854974 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources